TLSI (TriSalus Life Sciences) EPS (Basic) : $-1.12 (TTM As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is TriSalus Life Sciences EPS (Basic)?

TriSalus Life Sciences's basic earnings per share (Basic EPS) for the three months ended in Mar. 2025 was $-0.39. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2025 was $-1.12.

TriSalus Life Sciences's EPS (Diluted) for the three months ended in Mar. 2025 was $-0.39. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $-1.12.

TriSalus Life Sciences's EPS without NRI for the three months ended in Mar. 2025 was $-0.34. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2025 was -1.45.

During the past 3 years, the average EPS without NRI Growth Rate was 72.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 4 years, TriSalus Life Sciences's highest 3-Year average EPS without NRI Growth Rate was 72.60% per year. The lowest was 72.60% per year. And the median was 72.60% per year.

TriSalus Life Sciences EPS (Basic) Historical Data

The historical data trend for TriSalus Life Sciences's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TriSalus Life Sciences EPS (Basic) Chart

TriSalus Life Sciences Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

EPS (Basic)

-93.17

-161.55

-6.77

-1.31

TriSalus Life Sciences Quarterly Data
	Dec21	Mar22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EPS (Basic)	Get a 7-Day Free Trial								-0.60	-0.21	-0.12	-0.40	-0.39

TriSalus Life Sciences EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

TriSalus Life Sciences's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-30.045	-	0)	/	25.332
	=	-1.19

TriSalus Life Sciences's Basic EPS for the quarter that ended in Mar. 2025 is calculated as

Basic EPS (Q: Mar. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-10.375	-	0)	/	28.527
	=	-0.36

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.12

TriSalus Life Sciences (NAS:TLSI) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

TriSalus Life Sciences EPS (Basic) Related Terms

Thank you for viewing the detailed overview of TriSalus Life Sciences's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

TriSalus Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TriSalus Life Sciences Inc (NAS:TLSI) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

6272 W. 91st Avenue, Westminster, CO, USA, 80031

Website

https://www.trisaluslifesci.com

TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.

Executives

Bryan F. Cox	officer: Chief Scientific & Manufact.	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Jodi Devlin	officer: President, Therapeutics	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Jennifer Stevens	officer: Chief Regulatory Officer	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Richard Marshak	officer: Sr.VP, Corp. Dev. & Strategy	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Mary T Szela	director, officer: CEO and President	10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Sean Murphy	director, officer: Chief Financial Officer	C/O NOVAN, INC., 4222 EMPEROR BOULEVAND, SUITE 200, DURHAM NC 27703
Equity Ab Frankenius	10 percent owner	BOX 984, BORAS V7 SE-501 10
Arjun Jj Desai	director	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Mats Wahlstrom	director, 10 percent owner	500 GOLDEN RIDGE ROAD, SUITE 100, GOLDEN CO 80401
George Kelly Martin	director	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
James Alecxih	officer: President, Device Technology	C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Anil K. Singhal	director	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Steven C Katz	officer: Chief Medical Officer	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Von Eschenbach Andrew C.	director	C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Kerry R Hicks	director	C/O HEALTHGRADES.COM, 44 UNION BLVD SUITE 600, LAKEOOD CO 80228